atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

NEXT STORY
Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance
PREV STORY
Worldwide Homeopathic Medicine Industry to 2027 – Lucrative Gains from Robust Promotional and Marketing Activities Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

World Immunoassay Market Strategies and Trends Report 2022 to 2026: Immunoassay vs. PCR vs. Sequencing – A See-Saw Battle

author_avatar
NASDAQ Market News

Innovate Biopharmaceuticals’ Dose Response Data for Larazotide Acetate Demonstrating Its Unique Mechanism of Action and Applications in Diseases Caused by Increased Intestinal Permeability

RALEIGH, N.C., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”), a clinical ...

author_avatar
NASDAQ Market News

Erasca Reports Second Quarter 2021 Financial Results and Business Updates

author_avatar
NASDAQ Market News